The AIDS Clinical Trials Group (ACTG), the world's largest and longest established HIV research network, today announced the initiation of the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial, which will be conducted by the ACTG. ACTIV-2 includes both phase 2 and phase 3 evaluations of multiple promising investigational agents for treating early COVID-19 in a single trial.
Patients admitted with COVID-19 at select hospitals may now volunteer to enroll in a clinical trial to test the safety and efficacy of a potential new treatment for the disease. The Phase 3 randomized, controlled trial, known as ACTIV-3, and as a "master protocol," is designed to expand to test multiple kinds of monoclonal antibody treatments. It also can enroll additional volunteers in the middle of the trial, if a specific investigational treatment shows promise.
Rush University Medical Center, supported by the Family Larsson-Rosenquist Foundation, has produced a series of educational videos and mother-focused information sheets to train healthcare professionals in mothers' own milk (MOM) feeding practices in neonatal intensive care units (NICUs) worldwide.
A Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies (mAbs) to treat the disease. Researchers sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, are working with clinical sites to identify potential patient volunteers currently infected with SARS-CoV-2, the virus which causes COVID-19, who have mild to moderate disease not requiring hospitalization.
The Company of Biologists is the first not-for-profit publisher to commit to the Transformative Journal approach. The Company has offered Open Access publishing options since 2004 and two of its five journals are already fully Open Access. The Transformative Journal strategy signals more clearly the journals' commitment to move towards full Open Access, while a transition period allows the Company to provide publishing options that support all authors through this change in the publishing landscape.
Oryx - The International Journal of Conservation, is to become fully open access from 1 January 2021, making it free to read by anyone with an internet connection, anywhere in the world.
How long can seeds stay alive? That question is crucial for seed gene banks and research institutes working with plants and seeds. Therefore, a new seed longevity experiment has started in the Global Seed Vault. The experiment comprises seeds of 13 globally important crops, produced by project partners from all over the world, including Leibniz Institute of Plant Genetics and Crop Plant Research (IPK), and is planned to go on for a hundred of years from now on.
NASA astrophysicists and engineers are adapting detectors used by earthbound supercolliders and creating them the same way electronics companies produce all modern consumer devices, including cell phones and laptops.
While K-12 schools across Massachusetts are looking at options for reopening this fall in light of the COVID-19 pandemic, a new report says public schools should also be looking at another important issue for their future: diversity.
To help increase breastfeeding among premature infants, researchers at Rush University Medical Center will test the effects of an intervention that addresses barriers to breastfeeding.